In the latest trading session, 0.51 million iBio Inc (NASDAQ:IBIO) shares changed hands as the company’s beta touched 1.48. With the company’s most recent per share price at $1.41 changed hands at -$0.1 or -6.29% at last look, the market valuation stands at $13.97M. IBIO’s current price is a discount, trading about -388.65% off its 52-week high of $6.89. The share price had its 52-week low at $1.40, which suggests the last value was 0.71% up since then. When we look at iBio Inc’s average trading volume, we note the 10-day average is 0.78 million shares, with the 3-month average coming to 575.93K.
Analysts gave the iBio Inc (IBIO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended IBIO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. iBio Inc’s EPS for the current quarter is expected to be -0.32.
iBio Inc (NASDAQ:IBIO) trade information
Instantly IBIO was in red as seen in intraday trades today. With action -63.81%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -42.24%, with the 5-day performance at -63.81% in the red. However, in the 30-day time frame, iBio Inc (NASDAQ:IBIO) is -74.46% down. Looking at the short shares, we see there were 0.85 million shares sold at short interest cover period of 0.9 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3.6, meaning bulls need an upside of 60.83% from its recent market value. According to analyst projections, IBIO’s forecast low is 3.6 with 3.6 as the target high. To hit the forecast high, the stock’s price needs a -155.32% plunge from its current level, while the stock would need to soar -155.32% for it to hit the projected low.
iBio Inc (IBIO) estimates and forecasts
Year-over-year growth is forecast to reach 77.78% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 100k. 2 analysts are of the opinion that iBio Inc’s revenue for the current quarter will be 100k. The estimates for the next quarter sales put growth at -42.86%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 57.55%. The 2025 estimates are for iBio Inc earnings to increase by 60.55%, but the outlook for the next 5-year period is at 45.01% per year.
iBio Inc (NASDAQ:IBIO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.21% of iBio Inc shares while 26.65% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 28.72%.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund. With 73.14 shares estimated at $0.1 million under it, the former controlled 0.74% of total outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held about 0.46% of the shares, roughly 45.79 shares worth around $64566.0.
